A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease Abstract #105

Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Aim(s): To determine the whether CgA, NKA, NTproBNP can predict the presence of carcinoid heart disease in patients with carcinoid disease.
Materials and methods: Forty patients (23 males and 17 females) with carcinoid disease and either liver metastasis or carcinoid syndrome where recruited (age 64±11yrs, 58% males). We measured serum concentrations of: NKA (pancreastatin assay - Peptide Laboratory, Belfast), NTproBNP (Roche diagnostics) and CgA (pancreastatin assay - Reference Laboratory, Hammersmith). Each patient was screened by echocardiography for the presence of CHD. A diagnosis of CHD is made if there was typical thickening and shortening of the tricuspid or pulmonary valves resulting in regurgitation and/or stenosis. Scans were performed and analysed by a single operator. Receiver-operator characteristic plot analysis was used to determine the sensitivity and specificity of each of the biomarkers for the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong

To read results and conclusion, please login ...

Further abstracts you may be interested in

#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr Rebecca Dobson
Authors: Dobson R, Burgess M, Chadwick C, Vora J, ...
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2818 Is It That Rare?
Introduction: Carcinoid heart disease (CHD) is a rare and unique manifestation, It present in 50% of CS
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Saleha Babli
Authors: Babli S, Alzahrani W, Aldawish M, ...